Literature DB >> 25512239

Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?

Toine M Lodewick1, Thiemo J A van Nijnatten, Ronald M van Dam, Kim van Mierlo, Simon A W G Dello, Ulf P Neumann, Steven W M Olde Damink, Cornelis H C Dejong.   

Abstract

BACKGROUND: The impact of body composition on outcomes after surgery for colorectal liver metastases (CRLM) remains unclear. The aim of the present study was to determine the influence of sarcopenia, obesity and sarcopenic obesity on morbidity, disease-free (DFS) and overall survival (OS).
METHOD: Between 2005 and 2012, all patients undergoing a partial liver resection for CRLM in the Maastricht University Medical Centre, and who underwent computed tomography (CT) imaging within 3 months before liver surgery, were included. Body composition was primarily based on pre-operative CT measurements. Sarcopenia was based on total muscle area at the level of the third lumbar vertebra and predefined body mass index (BMI)- and gender-specific cut-off values for sarcopenia were used. Body fat percentages were calculated and the top 40% for men and women were considered obese.
RESULTS: Of the 171 included patients undergoing liver surgery for CRLM, 80 (46.8%) patients were sarcopenic, 69 (40.4%) obese and 49 (28.7%) sarcopenic obese. The presence of sarcopenia, obesity or sarcopenic obesity did not affect the complication rates. However, readmission rates were significantly increased in patients with (sarcopenic) obesity (P < 0.05). Surprisingly, obesity seemed to prolong OS (P = 0.021) and was identified as an independent predictor [hazard ratio (HR):0.58 and P = 0.046] for better OS. Sarcopenia and sarcopenic obesity did not affect DFS or OS.
CONCLUSION: Sarcopenia, obesity and sarcopenic obesity did not worsen DFS, OS and complication rates after a partial liver resection for CRLM.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 25512239      PMCID: PMC4402055          DOI: 10.1111/hpb.12373

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  36 in total

1.  Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection.

Authors:  R M van Dam; P O Hendry; M M E Coolsen; M H A Bemelmans; K Lassen; A Revhaug; K C H Fearon; O J Garden; C H C Dejong
Journal:  Br J Surg       Date:  2008-08       Impact factor: 6.939

2.  Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity.

Authors:  Martin Stockmann; Johan F Lock; Björn Riecke; Karsten Heyne; Peter Martus; Michael Fricke; Sina Lehmann; Stefan M Niehues; Michael Schwabe; Arne-Jörn Lemke; Peter Neuhaus
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

Review 3.  Multimodal management of colorectal liver metastases and the effect on regeneration and outcome after liver resection.

Authors:  Daniel Ansari; Magnus Bergenfeldt; Bobby Tingstedt; Roland Andersson
Journal:  Scand J Gastroenterol       Date:  2012-10-04       Impact factor: 2.423

Review 4.  Sarcopenic obesity: A Critical appraisal of the current evidence.

Authors:  C M M Prado; J C K Wells; S R Smith; B C M Stephan; M Siervo
Journal:  Clin Nutr       Date:  2012-07-17       Impact factor: 7.324

5.  The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery.

Authors:  Martin Stockmann; Johan F Lock; Maciej Malinowski; Stefan M Niehues; Daniel Seehofer; Peter Neuhaus
Journal:  HPB (Oxford)       Date:  2010-03       Impact factor: 3.647

Review 6.  The obesity paradox in the surgical population.

Authors:  Tabita M Valentijn; Wael Galal; Elke K M Tjeertes; Sanne E Hoeks; Hence J Verhagen; Robert Jan Stolker
Journal:  Surgeon       Date:  2013-03-09       Impact factor: 2.392

7.  Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.

Authors:  Benjamin H L Tan; Laura A Birdsell; Lisa Martin; Vickie E Baracos; Kenneth C H Fearon
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

8.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

Authors:  Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2008-06-06       Impact factor: 41.316

Review 9.  Expanding criteria for resectability of colorectal liver metastases.

Authors:  Timothy M Pawlik; Richard D Schulick; Michael A Choti
Journal:  Oncologist       Date:  2008-01

10.  Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases.

Authors:  Ronald M van Dam; Toine M Lodewick; Maartje A J van den Broek; Mechteld C de Jong; Jan Willem Greve; Rob L H Jansen; Marc H A Bemelmans; Ulf P Neumann; Steven W M Olde Damink; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2013-11-07       Impact factor: 3.647

View more
  35 in total

Review 1.  The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature.

Authors:  Savita Joglekar; Peter N Nau; James J Mezhir
Journal:  J Surg Oncol       Date:  2015-08-27       Impact factor: 3.454

2.  Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis.

Authors:  Katelin A Mirkin; Franklyn E Luke; Alexandra Gangi; Jose M Pimiento; Daniel Jeong; Christopher S Hollenbeak; Joyce Wong
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Diagnosing options in patient with sarcopenia.

Authors:  Battal Altun; Umit Cintosun; Ilker Tasci
Journal:  HPB (Oxford)       Date:  2015-07-02       Impact factor: 3.647

4.  Is Sarcopenic Obesity an Indicator of Poor Prognosis in Gastric Cancer Surgery? A Cohort Study in a Western Population.

Authors:  V Rodrigues; F Landi; S Castro; R Mast; N Rodríguez; A Gantxegi; J Pradell; M López-Cano; M Armengol
Journal:  J Gastrointest Surg       Date:  2020-07-13       Impact factor: 3.452

5.  Impact of the preoperative body composition indexes on intraoperative blood loss in patients undergoing pancreatoduodenectomy.

Authors:  Kenta Ishii; Yukihiro Yokoyama; Tomoki Ebata; Tsuyoshi Igami; Takashi Mizuno; Junpei Yamaguchi; Shunsuke Onoe; Nobuyuki Watanabe; Masato Nagino
Journal:  Surg Today       Date:  2020-06-20       Impact factor: 2.549

6.  Incisional hernia after open resections for colorectal liver metastases - incidence and risk factors.

Authors:  Jan H Nilsson; Peter Strandberg Holka; Christian Sturesson
Journal:  HPB (Oxford)       Date:  2016-03-10       Impact factor: 3.647

7.  Severe Preoperative Symptoms Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection.

Authors:  Heather A Lillemoe; Rebecca K Marcus; Bradford J Kim; Nisha Narula; Catherine H Davis; Qiuling Shi; Xin Shelley Wang; Thomas A Aloia
Journal:  Ann Surg Oncol       Date:  2019-08-14       Impact factor: 5.344

8.  Impact of Visceral Adiposity as Well as Sarcopenic Factors on Outcomes in Patients Undergoing Liver Resection for Colorectal Liver Metastases.

Authors:  Atsushi Kobayashi; Toshimi Kaido; Yuhei Hamaguchi; Shinya Okumura; Hisaya Shirai; Naoko Kamo; Shintaro Yagi; Kojiro Taura; Hideaki Okajima; Shinji Uemoto
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

9.  Body composition as reflected by intramuscular adipose tissue content may influence short- and long-term outcome following 2-stage liver resection for colorectal liver metastases.

Authors:  Toshimitsu Shiozawa; Yutaro Kikuchi; Tetsuji Wakabayashi; Kenichi Matsuo; Yuki Takahashi; Kuniya Tanaka
Journal:  Langenbecks Arch Surg       Date:  2020-08-26       Impact factor: 3.445

Review 10.  Clinical Implications of Sarcopenic Obesity in Cancer.

Authors:  Isabella P Carneiro; Vera C Mazurak; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.